E.E. Geduld’s Agile Therapeutics AGRX Stock Holding History

E.E. Geduld’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-5	Closed	-$93K	–	319
2015 Q1	$93K	Buy	+5	New	+$87.6K	0.06%	197

Other funds holding AGRX

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Adage Capital Partners

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

E.E. Geduld's AGRX Position: Q2 2015 in Review

E.E. Geduld sold out of Agile Therapeutics (AGRX) in Q2 2015, closing a stake of 5 shares — an estimated $93K sold.

E.E. Geduld first reported a position in AGRX in Q1 2015 and held it in 1 quarter. The position peaked at $93K in Q1 2015. 51 funds tracked by Wall St. Rank hold AGRX as of Q2 2015.

E.E. Geduld reported no remaining Agile Therapeutics position as of Q2 2015 after selling out during the quarter.
E.E. Geduld sold 5 Agile Therapeutics shares in Q2 2015, an estimated $93K.
E.E. Geduld first reported a position in Agile Therapeutics in Q1 2015 and held it in 1 quarter.
E.E. Geduld's Agile Therapeutics position peaked at $93K in Q1 2015.
51 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2015.

Based on E.E. Geduld's 13F filing for Q2 2015, filed 7 Aug 2015.